Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00788944 · ClinicalTrials.gov registry record · Phase 4

Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl

A Phase 4 study of Depression, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 4
Development phase
971
Enrollment target
20
Study locations

NCT00788944: Completed Phase 4 study of Depression, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

NCT00788944 is a Phase 4 study of Depression that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 971 participants, above the 785-participant average among 679 other Depression trials with a reported enrollment target (24% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00788944, a Phase 4 study of Depression, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 4
Development phase
971 participants
Enrollment target
20
Study locations

Study Summary

This is a study to determine the percentage of patients with depression who are treated with extended-release venlafaxine HCl (U.S. marketed brand Effexor XR®) who are Poor Metabolizers (based on the levels of the drug in the blood) at 2D6 (a system in the liver that breaks down some medications and other chemicals).

Conditions Studied

Depression

Interventions

  • PROCEDURE blood draw

Study Locations (20)

California

  • Pfizer Investigational Site - National City
  • Pfizer Investigational Site - Oceanside
  • Pfizer Investigational Site - Santa Ana
  • Pfizer Investigational Site - Temecula

Florida

  • Pfizer Investigational Site - Coral Gables
  • Pfizer Investigational Site - Lauderhill
  • Pfizer Investigational Site - West Palm Beach
  • Pfizer Investigational Site - West Palm Beach

Colorado

  • Pfizer Investigational Site - Colorado Springs
  • Pfizer Investigational Site - Denver

Connecticut

  • Pfizer Investigational Site - Cromwell
  • Pfizer Investigational Site - Milford

Kansas

  • Pfizer Investigational Site - Wichita
  • Pfizer Investigational Site - Wichita

Alabama

  • Pfizer Investigational Site - Birmingham

Arizona

  • Pfizer Investigational Site - Tuscon

Arkansas

  • Pfizer Investigational Site - Little Rock

Trial Details

FieldValue
Enrollment Target 971 participants
Start Date 2008-10
Est. Completion 2009-07
Phase Phase 4
Wyeth is now a wholly owned subsidiary of Pfizer

167 total trials

What the finished NCT00788944 record still lists

NCT00788944 is an interventional study that assigns participants to a tested intervention. The registered 971 participants enrollment target is mid-sized for trials with a published cap, above the 785-participant average among 679 other Depression trials with a reported enrollment target (24% higher).

The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which blood draw is the first listed.

NCT00788944 names 20 study sites across 11 states, led by California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT00788944 about?

NCT00788944 is a clinical study titled "Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl". This is a study to determine the percentage of patients with depression who are treated with extended-release venlafaxine HCl (U.S. marketed brand Effexor XR®) who are Poor Metabolizers (based on the levels of the drug in the blood) at 2D6 (a system in the liver that breaks down some medications and...

What is the current status of trial NCT00788944?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 971 participants. The study started on 2008-10. Estimated completion is 2009-07.

What conditions does trial NCT00788944 study?

This clinical trial studies the following conditions: Depression.

What interventions are being tested in trial NCT00788944?

The interventions under investigation include: blood draw (PROCEDURE).

Who is sponsoring clinical trial NCT00788944?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00788944 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00788944's enrollment target sits among peer trials

971 43rd of 679 higher than 637 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05354141 · 970 participants · Phase 3

    Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

  • NCT06948422 · 974 participants · Phase 3

    A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

  • NCT05600777 · 975 participants · Phase 3

    A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

  • NCT06541704 · 975 participants · Phase 3

    A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00788944, the US trial registry maintained by the National Library of Medicine. NCT00788944 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.